Form 4: Eli Lilly EVP Daniel Skovronsky Reports Stock Sales and Acquisition of Restricted Stock Units

Daniel Skovronsky, EVP, CSO & President of LRL & LLY Imm at Eli Lilly & Co, reported the sale of common stock and acquisition of restricted stock units on February 10, 2025, according to a Form 4 filing.

Summary

• On February 10, 2025, Daniel Skovronsky, an EVP at Eli Lilly & Co, reported selling shares of common stock at weighted average prices ranging from $862.49 to $866.10.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 11, 2024.
• Skovronsky also acquired 12,684 restricted stock units, each representing a contingent right to receive one share of Eli Lilly common stock, exercisable on February 1, 2026, and expiring on February 1, 2026.
• Following these transactions, Skovronsky directly owns 136,660.112 shares of Eli Lilly common stock.
• He also indirectly owns 72,359 shares through a trust and 3,257 shares through his spouse, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity. The transactions were pre-planned under a 10b5-1 trading plan, reducing the likelihood of a significant negative interpretation.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like executives and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Stakeholder Impact

• The stock sales by an executive could be perceived negatively by shareholders if not understood in the context of a pre-arranged trading plan.
• The acquisition of restricted stock units aligns the executive's interests with those of the shareholders.

Key Dates